Table 1

Key design criteria of the analysis

PopulationIndividuals newly diagnosed with CRC and FDR and SDR
InterventionDNA sequencing of all newly diagnosed CRC cases and cascade genetic testing of four or more FDR and SDR of identified LS cases
ComparatorCurrent strategy with IHC, BRAF V600E and DNA sequencing for a proportion of newly diagnosed CRC cases and cascade testing of four FDR and/or SDR
OutcomeQALYs saved
Model typeDecision trees integrated with Markov models
Time horizonLifetime/50 years
PerspectiveSwiss healthcare system
CostsSwiss francs (CHF)
Discounting3% per year
Cost-effectiveness thresholdCHF100000 per QALY
  • CRC, colorectal cancer; FDR, first-degree relative; IHC, immunohistochemistry; LS, Lynch syndrome; QALYs, quality-adjusted life years; SDR, second-degree relative.